CRISPR-Cas9 for treating hereditary diseases

被引:10
|
作者
Mani, Indra [1 ]
机构
[1] Univ Delhi, Dept Microbiol, Gargi Coll, New Delhi, India
关键词
FRAGILE-X-SYNDROME; TAY-SACHS-DISEASE; PLURIPOTENT STEM-CELLS; GENE-THERAPY; MOUSE MODEL; PARKINSON DISEASE; ALPHA-SYNUCLEIN; HEMOPHILIA-A; CGG REPEAT; CRISPR/CAS9;
D O I
10.1016/bs.pmbts.2021.01.017
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This chapter analyzes to use of the genome editing tool to the treatment of various genetic diseases. The genome editing method could be used to change the DNA in cells or organisms to understand their physiological response. Therefore, a key objective is to present general information about the use of the genome editing tool in a pertinent way. An emerging genome editing technology like a clustered regularly short palindromic repeats (CRISPR) is an extensively expended in biological sciences. CRISPR and CRISPR-associated protein 9 (CRISPR-Cas9) technique is being utilized to edit any DNA mutations associated with hereditary diseases to study in cells (in vitro) and animals (in vivo). Interestingly, CRISPR-Cas9 could be used to the investigation of treatments of various human hereditary diseases such as hemophila, beta-thalassemia, cystic fibrosis, Alzheimer's, Huntington's, Parkinson's, tyrosinemia, Duchnene muscular dystrophy, Tay-Sachs, and fragile X syndrome disorders. Furthermore, CRISPR-Cas9 could also be used in other diseases to the improvement of human health. Finally, this chapter discuss current progress to treatment for hereditary diseases using CRISPR-Cas9 technology and highlights associated challenges and future prospects.
引用
收藏
页码:165 / 183
页数:19
相关论文
共 50 条
  • [32] Implications of CRISPR-Cas9 Genome Editing Methods in Atherosclerotic Cardiovascular Diseases
    Goharrizi, Mohammad Ali Sheikh Beig
    Ghodsi, Saeed
    Memarjafari, Mohammad Reza
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (05)
  • [33] Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review
    Lee, Min Ho
    Shin, Jae Il
    Yang, Jae Won
    Lee, Keum Hwa
    Cha, Do Hyeon
    Hong, Jun Beom
    Park, Yeoeun
    Choi, Eugene
    Tizaoui, Kalthoum
    Koyanagi, Ai
    Jacob, Louis
    Park, Seoyeon
    Kim, Ji Hong
    Smith, Lee
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [34] Advances in therapeutic application of CRISPR-Cas9
    Sun, Jinyu
    Wang, Jianchu
    Zheng, Donghui
    Hu, Xiaorong
    [J]. BRIEFINGS IN FUNCTIONAL GENOMICS, 2020, 19 (03) : 164 - 174
  • [35] CRISPR-CAS9 in medicine, the saga continues
    Becu-Villalobos, Damasia
    [J]. MEDICINA-BUENOS AIRES, 2019, 79 (06) : 522 - 523
  • [36] CRISPR-Cas9 strikes out in cassava
    Rybicki, Edward P.
    [J]. NATURE BIOTECHNOLOGY, 2019, 37 (07) : 727 - 728
  • [37] The CRISPR-Cas9 system in Neisseria spp
    Zhang, Yan
    [J]. PATHOGENS AND DISEASE, 2017, 75 (04):
  • [38] Principles of DNA cleavage in CRISPR-Cas9
    Ahsan, Mohammad
    Nierzwicki, Qukasz
    East, Kyle W.
    Binz, Jonas
    Hsu, Rohaine V.
    Arantes, Pablo R.
    Skeens, Erin
    Pacesa, Martin
    Jinek, Martin
    Lisi, George P.
    Palermo, Giulia
    [J]. BIOPHYSICAL JOURNAL, 2023, 122 (03) : 170A - 170A
  • [39] Who owns CRISPR-Cas9 in Europe?
    András Kupecz
    [J]. Nature Biotechnology, 2014, 32 : 1194 - 1196
  • [40] Chemistry Nobel Honors CRISPR-Cas9
    You Li-Lan
    Sun Wei
    Yang Xiao-Qi
    Wang Yan-Li
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2020, 47 (11) : 1119 - 1126